ENTA News Alert Enanta Pharmaceuticals Inc (ENTA) 49.04 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enanta Pharmaceuticals Inc (ENTA) 49.04 $ENTA

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 8:03AM CST
For shareholders of Gilead Sciences it's practically been a dream year . Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni. ...
JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Hertz and Green Mountain are big market movers
AP - Tue Dec 23, 3:53PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
NBL: 48.50 (-0.48), BB.TO: 12.41 (-0.17), HTZ: 24.38 (-0.09), GMCR: 137.65 (+1.10), OCN: 14.88 (-0.14), NBR: 12.42 (-0.26), VNDA: 14.69 (+1.11), BBRY: 10.67 (-0.13), DRL: 3.38 (-0.02), BZH: 18.59 (+0.03), ENTA: 49.04 (+0.06), BA: 131.24 (+1.21), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), CHK: 19.84 (-0.45), TASR: 26.86 (+0.84)

Enanta Pharmaceuticals (ENTA) Jumps: Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 8:39AM CST
Enanta Pharmaceuticals, Inc. (ENTA) shares rose over 10% in the last trading session.
ENTA: 49.04 (+0.06), IG: 9.11 (-0.01)

AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 23, 8:19AM CST
What a difference a weekend makes. On Friday, when the Food and Drug Administration approved AbbVie 's Viekira Pak, it looked as if AbbVie had done Gilead Sciences a huge favor pricing its new hepatitis C drug on par with Gilead's Harvoni. ...
ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Enanta Is The Big Winner In The Hepatitis C War Between AbbVie And Gilead
George Rho - at Seeking Alpha - Tue Dec 23, 7:47AM CST

GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Express Scripts' Formulary Changes Create Buying Opportunities For Gilead And Enanta
Clinically Sound Investor - at Seeking Alpha - Tue Dec 23, 6:02AM CST

ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Express Scripts/AbbVie HCV deal should not be surprising
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:19AM CST

ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 8:17AM CST

OCN: 14.88 (-0.14), SGOC: 0.61 (-0.02), NVGN: 2.40 (-0.09), EXAS: 27.60 (+0.39), TGE: 2.11 (+0.15), CZR: 15.44 (+0.20), ENTA: 49.04 (+0.06), NQ: 4.32 (-0.36), PVG: 5.07 (+0.14), RDUS: 37.17 (+0.11), CANF: 3.70 (+0.01), NG: 2.82 (+0.10), SYN: 1.46 (-0.07), GILD: 91.29 (+1.84), VSCI: 0.76 (-0.07), CNET: 1.28 (-0.11), SVM: 1.25 (+0.09)

Rewards Outweigh Risk for Long-Term Equity Players: Featured Research on Pier 1 Imports, CarMax, Transocean, Enanta and Aratana
PR Newswire - Mon Dec 22, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pier 1 Imports (NYSE: PIR), CarMax (NYSE: KMX), Transocean (NYSE: RIG), Enanta (NASDAQ: ENTA), and Aratana (NASDAQ: PETX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KMX: 67.61 (-0.15), RIG: 18.77 (-0.37), PIR: 15.33 (-0.11), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06)

Stock Futures Point Higher; AbbVie Surges, Gilead Dives
at Investor's Business Daily - Mon Dec 22, 8:10AM CST
Stock futures were steady and positive ahead of Monday's open. Dow futures pointed 82.2 points above fair market value. Nasdaq 100 futures showed weak gains, up 7 points. S&P 500 futures climbed 7.8 points. The stock market today faces mixed...
ESRX: 85.48 (-0.40), CALM: 42.45 (-1.73), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06), WAG: 76.67 (+0.16)

HCV-related firms on the move premarket
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 6:53AM CST

ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

FDA approves AbbVie combo hepatitis C treatment
By LINDA A. JOHNSON - AP - Fri Dec 19, 7:32PM CST
TRENTON, N.J. (AP) — Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.
JNJ: 104.59 (+0.31), ENTA: 49.04 (+0.06)

Enanta Announces U.S. Food and Drug Administration Approves AbbVie's VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C Virus
Business Wire - Fri Dec 19, 4:55PM CST
--In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than two percent of patients experiencing virological failure
ENTA: 49.04 (+0.06)

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C
PR Newswire - Fri Dec 19, 4:45PM CST
The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK(TM), an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is the only FDA-approved regimen that contains three distinct mechanisms of action - NS5A inhibitor, NS3/4A protease inhibitor and a non-nucleoside NS5B polymerase inhibitor - that work together to attack the virus at three separate stages of the disease lifecycle to inhibit it from reproducing.
ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Abbvie's Hep C Regimen Approved, Marketing Battle With Gilead Up Next
at The Street - Fri Dec 19, 3:16PM CST
U.S. regulators approved a new hepatitis C therapy from Abbvie, heralding a new era of market competition with Gilead Sciences.
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

FDA clears AbbVie HCV combo
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 2:46PM CST

GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

PDUFA date approaches for AbbVie HCV combo therapy
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:41AM CST

ABBV: 66.21 (+1.86), ENTA: 49.04 (+0.06)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 7:19AM CST
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). NASDAQ has announced that the annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
ENTA: 49.04 (+0.06)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Beta Glucan Market Set to Exceed USD 31 Billion by 2030

Updated Category News Views 56

Exploring the Growth of the Beta Glucan Market The beta glucan market is experiencing remarkable growth, largely driven by increasing awareness of its health benefits. More and more consumers are recognizing the importance of supporting their immune systems and managing cholesterol levels, which has led to a surge in demand across numerous sectors, including...

Continue Reading
AiPPT.com: Crafting the Next Era of AI-Driven Presentations

Updated Category News Views 177

Transforming Presentations with AiPPT.com In the evolving landscape of digital work, AiPPT.com stands out as a leading provider of AI-native tools that are reshaping the way presentations are crafted. As an advanced AI presentation maker, AiPPT.com is committed to enhancing user experiences by making the process of creating engaging and professional presentations much...

Continue Reading
Acme Mills Launches Natura: Revolutionizing Sustainable Fabrics

Updated Category News Views 244

Revolutionizing Textile Innovation with Natura Acme Mills Company, a recognized pioneer in textile manufacturing, has proudly unveiled its latest innovation, Natura. This new line of bio-based polylactic acid (PLA) fabrics aims to replace traditional petroleum-based materials such as PET, PP, and Nylon. With Natura, Acme Mills is not just promoting a product; it is...

Continue Reading
Class Action Alert for C3.ai, Inc. Investors - Join Now!

Updated Category News Views 123

Opportunity for C3.ai, Inc. Shareholders to Join Class Action Attention, shareholders of C3.ai, Inc. (NYSE: AI). A significant class action suit is currently underway, and your involvement could be crucial. If you purchased shares during the class period, there may be an opportunity for you to participate in a recovery process without the requirement of being a lead...

Continue Reading
EyePoint Pharmaceuticals: Innovations and Financial Insights

Updated Category News Views 224

EyePoint Pharmaceuticals Set to Showcase Q2 Financials EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company dedicated to developing advanced therapeutics for serious retinal diseases, plans to share its second quarter 2025 financial results. This announcement will be accompanied by a live conference call and webcast on a scheduled day, promising to provide...

Continue Reading